Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who are reasonably functional in daily life (rated 0–2 on a standard medical activity scale)
• People with a confirmed diagnosis of non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body
• People whose cancer has a specific type of genetic change (mutation) in the EGFR gene — either the mutations in Cohort 1 (G719X, L861Q, or S768I) or an exon 20 insertion mutation in Cohort 2
• People who have not previously been treated with EGFR-targeted therapy drugs (called EGFR-TKIs)
• People whose cancer has worsened after, or who could not tolerate, at least one round of platinum-based chemotherapy
• People who have at least one measurable area of cancer detectable on scans, according to standard measurement guidelines

Who may not be able to join:

• People who have previously received any EGFR-TKI (a type of targeted cancer drug)
• People with active, symptomatic cancer spread to the brain — though people with stable, symptom-free brain lesions may still be considered (confirm with trial site)
• People with serious heart conditions, including a specific abnormal heart rhythm reading (QTc of 450 ms or above) or a heart attack within the past 6 months
• People with an active hepatitis B, hepatitis C, or HIV infection
• People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.